4/A: ARS Pharmaceuticals Director Pratik Shah Amends Form 4 Filing Regarding Trust Transfers

Pratik Shah, a director and 10% owner of ARS Pharmaceuticals, amended a previous Form 4 filing to clarify details regarding the transfer of shares from The Pratik Shah Living Trust to two irrevocable trusts for the benefit of his sons.

Summary

• Pratik Shah, a director and 10% owner of ARS Pharmaceuticals, filed an amendment to a previous Form 4 filing.
• The amendment concerns a transaction dated June 4, 2024, where shares were transferred from The Pratik Shah Living Trust dated June 15, 2011.
• Specifically, 1,332,900 shares were transferred to The Light Irrevocable Trust #1, and another 1,332,900 shares were transferred to The Star Irrevocable Trust #1.
• Both irrevocable trusts have an adult son of Pratik Shah as a beneficiary.
• The transfers were made in exchange for trust assets of equal value under an asset substitution power authorized under the terms of each trust.
• Pratik Shah, Ph.D., serves as the trustee of The Pratik Shah Living Trust dated June 15, 2011.
• The amendment was filed solely to replace Footnote 1 in the original Form 4 filed on June 6, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a share transfer within a family trust. It doesn't inherently indicate positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market.

Related Party Transactions

• The transfer of shares to trusts benefiting the director's sons constitutes a related party transaction.

Stakeholder Impact

• The transaction itself is unlikely to have a direct impact on stakeholders, as it is a transfer within a family trust and does not involve a sale on the open market.

Key Dates